Tapinarof - Generic Drug Details

What are the generic sources for tapinarof and what is the scope of freedom to operate?

Tapinarof is the generic ingredient in one branded drug marketed by Organon Llc and is included in one NDA. There are eleven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Tapinarof has eighty patent family members in thirty-nine countries.

One supplier is listed for this compound.

Summary for tapinarof

International Patents:	80
US Patents:	11
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	60
Clinical Trials:	16
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for tapinarof
What excipients (inactive ingredients) are in tapinarof?	tapinarof excipients list
DailyMed Link:	tapinarof at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for tapinarof

Constraining patent/regulatory exclusivity:

10,647,649

Dosage:

CREAM;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for tapinarof

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Northwestern University	EARLY_PHASE1
Teva Pharmaceuticals USA	PHASE3
Teva Pharmaceuticals, Inc.	PHASE3

See all tapinarof clinical trials

Pharmacology for tapinarof

Drug Class	Aryl Hydrocarbon Receptor Agonist
Mechanism of Action	Aryl Hydrocarbon Receptor Agonists

Anatomical Therapeutic Chemical (ATC) Classes for tapinarof

D05AX	Other antipsoriatics for topical use
D05A	ANTIPSORIATICS FOR TOPICAL USE
D05	ANTIPSORIATICS
D	Dermatologicals

US Patents and Regulatory Information for tapinarof

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon Llc	VTAMA	tapinarof	CREAM;TOPICAL	215272-001	May 23, 2022		RX	Yes	Yes	11,458,108		Y
Organon Llc	VTAMA	tapinarof	CREAM;TOPICAL	215272-001	May 23, 2022		RX	Yes	Yes
Organon Llc	VTAMA	tapinarof	CREAM;TOPICAL	215272-001	May 23, 2022		RX	Yes	Yes	10,195,160		Y
Organon Llc	VTAMA	tapinarof	CREAM;TOPICAL	215272-001	May 23, 2022		RX	Yes	Yes	10,647,649			Y

International Patents for tapinarof

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2016185428
Taiwan	I705831
Mexico	2020004785	PROCESO PARA PREPARAR TAPINAROF. (PROCESS FOR PREPARING TAPINAROF.)
Peru	20180038	COMPOSICIONES FARMACEUTICAS TOPICAS

Market Dynamics and Financial Trajectory for Tapinarof

Last updated: July 28, 2025

---

Introduction

Tapinarof (formerly known as RX-02 or CS-014) is an emerging phosphorescent therapeutic agent developed by Dermavant Sciences, targeting inflammatory dermatological conditions such as plaque psoriasis, atopic dermatitis, and vitiligo. As a selective aryl hydrocarbon receptor (AhR) agonist, tapinarof modulates immune responses and promotes skin barrier function, offering a novel approach within dermatology's expanding pharmacotherapy landscape. This detailed analysis explores the market dynamics shaping tapinarof’s trajectory and assesses its potential financial impact on stakeholders.

---

Market Landscape and Unmet Needs

Growing Dermatology Market

The global dermatology market reached approximately $24 billion in 2022, with expectations of compound annual growth rate (CAGR) of 8% through 2030 (source: Grand View Research). Driven by increasing prevalence of chronic inflammatory skin conditions, demographic shifts, and rising awareness, the market presents substantial opportunities. Key conditions targeted by tapinarof—psoriasis, atopic dermatitis, and vitiligo—are characterized by significant morbidity and unmet therapeutic needs, particularly for patients unresponsive or intolerant to existing treatments.

Unmet Needs in Targeted Indications

• Plaque psoriasis: While biologics dominate the treatment landscape, many patients seek topical alternatives due to safety concerns or contraindications, underscoring ongoing demand for effective, steroid-sparing agents.

• Atopic dermatitis: A complex disease with limited safe long-term options; current therapies are often corticosteroids or immunomodulators with adverse effects limiting adherence.

• Vitiligo: Lacking FDA-approved systemic or topical treatments, with high patient demand for impactful therapies.

Tapinarof’s mechanism suggests a potential to fill these gaps by providing a non-steroidal, topical option with favorable safety profiles.

---

Regulatory and Development Status

Recent Approvals and Clinical Milestones

In July 2022, the U.S. Food and Drug Administration (FDA) approved Winlevi® (clascotriene) for scalp and body seborrheic dermatitis, but tapinarof itself is a primary candidate for topical applications targeting psoriasis and dermatitis.

In February 2022, Dermavant reported positive Phase 3 results (PSOARING 1 and 2), demonstrating significant efficacy and safety in plaque psoriasis, fulfilling key regulatory endpoints. The FDA approved tapinarof cream 1% for plaque psoriasis in 2022 under the brand Vtama®.

Ongoing trials for atopic dermatitis and vitiligo—such as the Phase 3 trial for atopic dermatitis—highlight the company’s strategic pipeline expansion. The regulatory trajectory remains favorable, bolstered by robust efficacy and safety data.

---

Market Adoption Dynamics

Physician and Patient Acceptance

Clinicians’ receptivity hinges on tapinarof’s efficacy, safety, and convenience. Its steroid-sparing profile enhances its attractiveness amid concerns over long-term corticosteroid use. Early market data indicates high initial adoption in dermatology practices, especially for patients seeking steroid-free options, especially pediatric populations and those with comorbidities.

Pricing and Reimbursement

Pricing strategies will play a pivotal role. Given the typical cost of topicals and biologics, Dermavant will likely position tapinarof as a premium topical therapy. Reimbursement trends favor novel mechanisms, especially if real-world evidence demonstrates cost-effective outcomes, reducing overall disease burden.

Market Penetration Barriers

• Competitive landscape: Existing topicals (calcipotriol, corticosteroids), biologics, and systemic agents challenge determination of market share.

• Physician familiarity: Adoption depends on clinical guideline updates embedding tapinarof as a standard of care for specific indications.

• Patient adherence: Ease of use, frequency of application, and perceived efficacy influence long-term adherence.

---

Competitive Landscape

Tapinarof’s key competitors include established topical therapies: corticosteroids, vitamin D analogs, calcineurin inhibitors, and emerging biologics. Novel entrants or formulations—e.g., crisaborole (FDA-approved for eczema) or burosumab (for rare conditions)—highlight the move towards mechanism-specific therapies.

Biologics like secukinumab, etanercept, and risankizumab dominate systemic treatment but are less ideal for long-term topical management or mild-to-moderate cases.

Differentiator: Tapinarof’s non-steroidal, immunomodulatory profile offers a distinct advantage, especially if long-term safety is proven, enabling greater market penetration.

---

Financial Trajectory

Revenue Projections

Based on initial launch data and clinical trial outcomes, Dermavant anticipates revenues in the range of $200-$400 million within the first three years of commercialization for psoriasis alone, reaching over $1 billion by 2027 if expansion into other indications materializes.

Forecast factors include:

• Market penetration: Estimated at 10-15% of the topical psoriasis market within five years.
• Pricing: An average wholesale price (AWP) of approximately $600-700 per tube/month, reflective of premium dermatology products.
• Reimbursement landscape: Favorable, with payers aligning with the therapy's safety and efficacy benefits.

Cost Considerations

Development costs are balanced against anticipated revenues. Investment in marketing, post-marketing studies, and pipeline expansion influences net profitability. Dermavant’s strategic emphasis on expanding indications could significantly augment financial upside.

Long-term Outlook

As clinical trials for atopic dermatitis and vitiligo reach pivotal milestones, the revenue footprint expands. Market exclusivity—assuming patent protections extending into the late 2030s—provides a revenue window to recoup investments and fund further innovation.

---

Regulatory and Commercial Risks

• Regulatory hurdles: Future indications require extensive evidence. Delays or setbacks could impair financial projections.
• Market competition: Rapid entry by biosimilars or new modalities threatens market share.
• Pricing pressures: Payers may seek discounts or formulary restrictions, impacting margins.
• Clinical efficacy concerns: Any safety issues or modest efficacy could diminish uptake.

---

Conclusion

Tapinarof's emergence as a first-in-class topical AhR agonist positions it favorably in a growing dermatology market. Its unique mechanism, combined with recent FDA approval and positive clinical data, underscores its potential as a disruptor in topical inflammatory therapies. The financial trajectory appears promising, contingent on strategic commercialization, effective market penetration, and successful indication expansion.

---

Key Takeaways

• Tapinarof benefits from a significant unmet need in psoriasis, atopic dermatitis, and vitiligo, offering a novel mechanism with a favorable safety profile.
• Rapid regulatory approval and positive Phase 3 results underpin robust market entry prospects.
• High revenue potential hinges on effective commercialization, payer acceptance, and expansion into new dermatological indications.
• Competitive advantage stems from its non-steroidal, immunomodulatory profile, appealing to both physicians and patients.
• Risks include regulatory delays, market competition, and payer negotiation dynamics, which could influence long-term profitability.

---

FAQs

1. What makes tapinarof different from existing topical treatments?
Unlike corticosteroids or vitamin D analogs, tapinarof is a selective AhR agonist that modulates immune responses without steroid-associated side effects, offering a safer long-term topical option.

2. Which conditions has tapinarof received FDA approval for?
As of 2022, tapinarof has been approved for the treatment of plaque psoriasis, marketed as Vtama®.

3. How does tapinarof’s market potential compare to biologic therapies?
While biologics dominate systemic treatment, tapinarof’s topical formulation targets mild-to-moderate cases and offers advantages, including safety, cost, and patient preference, positioning it as a complementary therapy rather than a direct competitor.

4. What are the key challenges in bringing tapinarof to market?
Challenges include market penetration amid established therapies, payer reimbursement negotiations, and expanding indications through large-scale clinical trials.

5. What is the outlook for tapinarof’s use in atopic dermatitis and vitiligo?
Positive Phase 3 trial results bolster confidence that regulatory approval for these indications is forthcoming, which could significantly increase its market footprint and revenue potential.

---

References

[1] Grand View Research. (2022). Dermatology Market Size, Share & Trends Analysis.
[2] Dermavant Sciences. (2022). FDA Approval of Vtama® (Tapinarof) Cream.
[3] FDA. (2022). Press Release on Psoriasis Treatment Approvals.
[4] MarketWatch. (2023). Dermatology Drug Market Trends and Outlook.
[5] ClinicalTrials.gov. (2022). Tapinarof Clinical Trial Registry Data.